Idi na sadržaj

Onkologija

Liječenje anemije

Sredstva za stimulaciju eritropoeze

Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (otvara se novi prozor)

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee

Izvor‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

Indeks‎: PubMed 29471514

DOI‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 (otvara se novi prozor)

Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. (otvara se novi prozor)

Baz R, Walker E, Choueiri TK, Abou Jawde R, Brand C, McGowan B, Yiannaki E, Andresen S, Hussein MA.

Izvor‎: Acta Haematol 2007;117(3):162-7.

Indeks‎: PubMed 17148935

DOI‎: 10.1159/000097464

https://www.ncbi.nlm.nih.gov/pubmed/17148935 (otvara se novi prozor)

Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial. (otvara se novi prozor)

Beguin Y, Maertens J, De Prijck B, Schots R, Seidel L, Bonnet C, Hafraoui K, Willems E, Vanstraelen G, Servais S, Jaspers A, Fillet G, Baron F.

Izvor‎: Am J Hematol 2013;88(12):990-6.

Indeks‎: PubMed 23873823

DOI‎: 10.1002/ajh.23552

https://www.ncbi.nlm.nih.gov/pubmed/23873823 (otvara se novi prozor)

Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. (otvara se novi prozor)

Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Würschmidt F, Petry KU, Kimmig R, Elling D, Thomssen C, von Minckwitz G, Möbus V, Hinke A, Kümmel S, Budach V, Lichtenegger W, Schmid P.

Izvor‎: J Clin Oncol 2011;29(28):3791-7.

Indeks‎: PubMed 21860000

DOI‎: 10.1200/JCO.2010.30.4899

https://www.ncbi.nlm.nih.gov/pubmed/21860000 (otvara se novi prozor)

Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. (otvara se novi prozor)

Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE.

Izvor‎: Cancer 2012;118(3):848-55.

Indeks‎: PubMed 21751205

DOI‎: 10.1002/cncr.26341

https://www.ncbi.nlm.nih.gov/pubmed/21751205 (otvara se novi prozor)

Management of anemia in cancer patients. (otvara se novi prozor)

Calabrich A, Katz A.

Izvor‎: Future Oncol 2011;7(4):507-17.

Indeks‎: PubMed 21463140

DOI‎: 10.2217/fon.11.24

https://www.ncbi.nlm.nih.gov/pubmed/21463140 (otvara se novi prozor)

The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. (otvara se novi prozor)

Djavan B, Laze J, Eckersberger E, Finkelstein J, Agalliu I, Lepor H.

Izvor‎: BJU Int 2011;108(10):1582-7.

Indeks‎: PubMed 21443653

DOI‎: 10.1111/j.1464-410X.2011.10173.x

https://www.ncbi.nlm.nih.gov/pubmed/21443653 (otvara se novi prozor)

Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. (otvara se novi prozor)

Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V.

Izvor‎: J Clin Oncol 2010;28(13):2239-45.

Indeks‎: PubMed 20368566

DOI‎: 10.1200/JCO.2009.25.1835

https://www.ncbi.nlm.nih.gov/pubmed/20368566 (otvara se novi prozor)

Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation. (otvara se novi prozor)

Fujisaka Y, Sugiyama T, Saito H, Nagase S, Kudoh S, Endo M, Sakai H, Ohashi Y, Saijo N.

Izvor‎: Br J Cancer 2011;105(9):1267-72.

Indeks‎: PubMed 21959870

DOI‎: 10.1038/bjc.2011.395

https://www.ncbi.nlm.nih.gov/pubmed/21959870 (otvara se novi prozor)

Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome. (otvara se novi prozor)

Garelius HK, Johnston WT, Smith AG, Park S, de Swart L, Fenaux P, Symeonidis A, Sanz G, Čermák J, Stauder R, Malcovati L, Mittelman M, van de Loosdrecht AA, van Marrewijk CJ, Bowen D, Crouch S, de Witte TJ, Hellström-Lindberg E.

Izvor‎: J Intern Med 2017;281(3):284-99.

Indeks‎: PubMed 27926979

DOI‎: 10.1111/joim.12579

https://www.ncbi.nlm.nih.gov/pubmed/27926979 (otvara se novi prozor)

How I treat cancer-associated anemia. (otvara se novi prozor)

Gilreath JA, Rodgers GM

Izvor‎: Blood 2020;136(7):801-13.

Indeks‎: PubMed 32556170

DOI‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 (otvara se novi prozor)

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (otvara se novi prozor)

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

Izvor‎: Eur J Haematol. 2023 110(4):354-61.

Indeks‎: PubMed 36480004

DOI‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ (otvara se novi prozor)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (otvara se novi prozor)

Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I.

Izvor‎: Cancer 2013;119(1):107-14.

Indeks‎: PubMed 22744794

DOI‎: 10.1002/cncr.27686

https://www.ncbi.nlm.nih.gov/pubmed/22744794 (otvara se novi prozor)

Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. (otvara se novi prozor)

Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Runnebaum IB, Hinke A, Kreienberg R, Untch M; on behalf of the AGO Breast Study Group.

Izvor‎: J Natl Cancer Inst 2013;105(14):1018-26.

Indeks‎: PubMed 23860204

DOI‎: 10.1093/jnci/djt145

https://www.ncbi.nlm.nih.gov/pubmed/23860204 (otvara se novi prozor)

Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials. (otvara se novi prozor)

Ohashi Y, Uemura Y, Fujisaka Y, Sugiyama T, Ohmatsu H, Katsumata N, Okamoto R, Saijo N, Hotta T.

Izvor‎: Cancer Sci 2013;104(4):481-5.

Indeks‎: PubMed 23331490

DOI‎: 10.1111/cas.12105

https://www.ncbi.nlm.nih.gov/pubmed/23331490 (otvara se novi prozor)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (otvara se novi prozor)

Pashos CL, Larholt K, Fraser KA, McKenzie RS, Senbetta M, Piech CT.

Izvor‎: Support Care Cancer 2012;20(1):159-65.

Indeks‎: PubMed 21359879

DOI‎: 10.1007/s00520-010-1083-7

https://www.ncbi.nlm.nih.gov/pubmed/21359879 (otvara se novi prozor)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (otvara se novi prozor)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Izvor‎: Leuk Lymphoma. 2019;60(9):2324-7.

Indeks‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (otvara se novi prozor)

Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial. (otvara se novi prozor)

Pronzato P, Cortesi E, van der Rijt CC, Bols A, Moreno-Nogueira JA, de Oliveira CF, Barrett-Lee P, Ostler PJ, Rosso R; for the EPO-INT-47 Study Group.

Izvor‎: Oncologist 2010;15(9):935-43.

Indeks‎: PubMed 20798194

DOI‎: 10.1634/theoncologist.2009-0279

https://www.ncbi.nlm.nih.gov/pubmed/20798194 (otvara se novi prozor)

Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. (otvara se novi prozor)

Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, Collins H, Crawford J.

Izvor‎: Lung Cancer 2012;76(3):478-85.

Indeks‎: PubMed 22277104

DOI‎: 10.1016/j.lungcan.2011.12.015

https://www.ncbi.nlm.nih.gov/pubmed/22277104 (otvara se novi prozor)

Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia. (otvara se novi prozor)

Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, Díez-Campelo M, Bailén A, Collado R, Vicente A, Arnan M, Valcarcel D, Arilla MJ, Zamora L, Benlloch L, Sanz G.

Izvor‎: Eur J Haematol 2016;97(1):33-8.

Indeks‎: PubMed 26341961

DOI‎: 10.1111/ejh.12679

https://www.ncbi.nlm.nih.gov/pubmed/26341961 (otvara se novi prozor)

Intravenozno željezo

Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (otvara se novi prozor)

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee

Izvor‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

Indeks‎: PubMed 29471514

DOI‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 (otvara se novi prozor)

Intravenous iron in oncology. (otvara se novi prozor)

Auerbach M, Ballard H.

Izvor‎: J Natl Compr Canc Netw 2008;6(6):585-92.

Indeks‎: PubMed 18597712

https://www.ncbi.nlm.nih.gov/pubmed/18597712 (otvara se novi prozor)

Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. (otvara se novi prozor)

Calleja JL, Delgado S, Del Val A, Hervás A, Larraona JL, Terán Á, Cucala M, Mearin F; Colon Cancer Study Group.

Izvor‎: Int J Colorectal Dis 2016;31(3):543-51.

Indeks‎: PubMed 26694926

DOI‎: 10.1007/s00384-015-2461-x

https://www.ncbi.nlm.nih.gov/pubmed/26694926 (otvara se novi prozor)

How I treat cancer-associated anemia. (otvara se novi prozor)

Gilreath JA, Rodgers GM

Izvor‎: Blood 2020;136(7):801-13.

Indeks‎: PubMed 32556170

DOI‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 (otvara se novi prozor)

Total dose iron dextran infusion in cancer patients: is it SaFe2+? (otvara se novi prozor)

Gilreath JA, Stenehjem DD, Rodgers GM.

Izvor‎: J Natl Compr Canc Netw 2012;10(5):669-76.

Indeks‎: PubMed 22570295

https://www.ncbi.nlm.nih.gov/pubmed/22570295 (otvara se novi prozor)

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (otvara se novi prozor)

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

Izvor‎: Eur J Haematol. 2023 110(4):354-61.

Indeks‎: PubMed 36480004

DOI‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ (otvara se novi prozor)

Intravenous iron therapy to treat anemia in oncology: a mapping review of randomized controlled trials. (otvara se novi prozor)

Lim J, Auerbach M, MacLean B, Al-Sharea A, Richards T

Izvor‎: Curr Oncol. 2023 24;30(9):7836-51.

Indeks‎: PubMed 37754484

DOI‎: 10.3390/curroncol30090569

https://pubmed.ncbi.nlm.nih.gov/37754484/ (otvara se novi prozor)

The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. (otvara se novi prozor)

Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B.

Izvor‎: Cochrane Database Syst Rev 2016;(2):CD009624.

Indeks‎: PubMed 26845108

DOI‎: 10.1002/14651858.CD009624.pub2

https://www.ncbi.nlm.nih.gov/pubmed/26845108 (otvara se novi prozor)

Perioperative anemia management in colorectal cancer patients: a pragmatic approach. (otvara se novi prozor)

Muñoz M, Gómez-Ramírez S, Martín-Montañez E, Auerbach M.

Izvor‎: World J Gastroenterol 2014;20(8):1972-85.

Indeks‎: PubMed 24587673

DOI‎: 10.3748/wjg.v20.i8.1972

https://www.ncbi.nlm.nih.gov/pubmed/24587673 (otvara se novi prozor)

Practical clinical consensus guidelines for the management of cancer associated anemia in low- and middle-income countries. (otvara se novi prozor)

Parikh PM, Aggarwal S, Biswas G, Gulia S, Agarwala V, Basade M, Mohapatra PN, Vamshi KM, Warrier A, Prasad K, Roy P, Chandrakant MV, Malhotra H, Hingmire S, Paul D, Maniar V, Gupta A, Panda SS, Samar A, Rohatgi N, Dattatreya S, Krishnamurthy M, Thirumalairaj R

Izvor‎: South Asian J Cancer. 2023 15;12(2):93-9.

Indeks‎: PubMed 37969669

DOI‎: 10.1055/s-0043-1771445

https://pubmed.ncbi.nlm.nih.gov/37969669/ (otvara se novi prozor)

Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. (otvara se novi prozor)

Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, Colucci G, Desogus A, Gamucci T, Pappalardo A, Fornarini G, Pozzi P, Fabi A, Labianca R, Di Costanzo F, Secondino S, Crucitta E, Apolloni F, Del Santo A, Siena S.

Izvor‎: J Clin Oncol 2008;26(10):1619-25.

Indeks‎: PubMed 18375891

DOI‎: 10.1200/JCO.2007.12.2051

https://www.ncbi.nlm.nih.gov/pubmed/18375891 (otvara se novi prozor)

Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. (otvara se novi prozor)

Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S.

Izvor‎: J Cancer Res Clin Oncol 2012;138(2):179-87.

Indeks‎: PubMed 21972052

DOI‎: 10.1007/s00432-011-1072-3

https://www.ncbi.nlm.nih.gov/pubmed/21972052 (otvara se novi prozor)

Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. (otvara se novi prozor)

Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, Tesch H, Rohrberg R, Marschner N.

Izvor‎: Ann Oncol 2013;24(2):475-82.

Indeks‎: PubMed 23071262

DOI‎: 10.1093/annonc/mds338

https://www.ncbi.nlm.nih.gov/pubmed/23071262 (otvara se novi prozor)

Expert consensus guidelines: intravenous iron uses, formulations, administration, and management of reactions. (otvara se novi prozor)

Van Doren L, Steinheiser M, Boykin K, Taylor KJ, Menendez M, Auerbach M

Izvor‎: Am J Hematol 2024;99(7):1338-48.

Indeks‎: PubMed 38282557

DOI‎: 10.1002/ajh.27220

https://pubmed.ncbi.nlm.nih.gov/38282557/ (otvara se novi prozor)

ONKOLOGIJA
Liječenje anemije
hrvatski
Liječenje anemije
https://assetsnffrgf-a.akamaihd.net/assets/ct/d8f8c0370e/images/syn_placeholder_sqr.png

Odbor za kontaktiranje s bolnicama (OKB)

Kontaktirajte predstavnike Jehovinih svjedoka koji će vam rado odgovoriti na pitanja vezana uz liječenje Jehovinih svjedoka.

Kontakt

Preuzmite medicinske informacije

Saznajte više o strategijama za kontroliranje krvarenja i anemije bez primjene transfuzije krvi, vjerskim uvjerenjima i etičkim principima Jehovinih svjedoka kad je riječ o liječenju te pronađite Odbore za kontaktiranje s bolnicama diljem svijeta.

Pregledaj preuzete sadržaje

Filmovi

Pristup liječenju te medicinskim i etičkim pitanjima. Namijenjeno liječnicima čiji su pacijenti Jehovini svjedoci.

Pogledajte videosadržaje